These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18172278)

  • 1. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
    Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
    Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.
    Kottke T; Thompson J; Diaz RM; Pulido J; Willmon C; Coffey M; Selby P; Melcher A; Harrington K; Vile RG
    Clin Cancer Res; 2009 Jan; 15(2):561-9. PubMed ID: 19147761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
    Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
    Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small extracellular vesicles carrying reovirus, tumor antigens, interferon-β, and damage-associated molecular patterns for efficient tumor treatment.
    Shuwari N; Inoue C; Ishigami I; Jingushi K; Kamiya M; Kawakami S; Tsujikawa K; Tachibana M; Mizuguchi H; Sakurai F
    J Control Release; 2024 Oct; 374():89-102. PubMed ID: 39122217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
    Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
    Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
    Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
    Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
    Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
    Berkeley RA; Steele LP; Mulder AA; van den Wollenberg DJM; Kottke TJ; Thompson J; Coffey M; Hoeben RC; Vile RG; Melcher A; Ilett EJ
    Cancer Immunol Res; 2018 Oct; 6(10):1161-1173. PubMed ID: 30209061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
    Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
    Pandha HS; Heinemann L; Simpson GR; Melcher A; Prestwich R; Errington F; Coffey M; Harrington KJ; Morgan R
    Clin Cancer Res; 2009 Oct; 15(19):6158-66. PubMed ID: 19773377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
    Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
    Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
    Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
    Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency
    Mohamed A; Clements DR; Gujar SA; Lee PW; Smiley JR; Shmulevitz M
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31748391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
    Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R
    Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
    Peng KW; Myers R; Greenslade A; Mader E; Greiner S; Federspiel MJ; Dispenzieri A; Russell SJ
    Gene Ther; 2013 Mar; 20(3):255-61. PubMed ID: 22476202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
    Gujar SA; Clements D; Dielschneider R; Helson E; Marcato P; Lee PW
    Br J Cancer; 2014 Jan; 110(1):83-93. PubMed ID: 24281006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Viral Therapy Using Reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
    Mohamed A; Smiley JR; Shmulevitz M
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.